NeurogesX (NGSX) Falls After FDA Briefing Documents
Tweet
Share
E-mailGet Alerts NGSX Hot Sheet
Join SI Premium – FREE
NeurogesX, Inc. (Nasdaq: NGSX) is seeing pressure as FDA briefing documents are posted. Link
Comments look negative.
Shares last traded at $0.91, down 21%.
Comments look negative.
Shares last traded at $0.91, down 21%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Jannik Sinner says he will not compete at US Open due to injury
- Trump admin taps former JPMorgan Chase exec Matt Zames to advise social security agency - CNBC
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
